Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy.

Gervasoni C, Ridolfo AL, Trifirò G, Santambrogio S, Norbiato G, Musicco M, Clerici M, Galli M, Moroni M.

AIDS. 1999 Mar 11;13(4):465-71.

PMID:
10197374
2.

Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.

Mallal SA, John M, Moore CB, James IR, McKinnon EJ.

AIDS. 2000 Jul 7;14(10):1309-16.

PMID:
10930144
4.

Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy.

Mulligan K, Tai VW, Algren H, Abrams DI, Leiser RJ, Lo JC, Schambelan M.

J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):443-8.

PMID:
11391163
5.

Antiretroviral therapy affects the composition of weight loss in HIV infection: implications for clinical nutrition.

Maia BS, Engelson ES, Wang J, Kotler DP.

Clin Nutr. 2005 Dec;24(6):971-8. Epub 2005 Aug 10.

PMID:
16095765
6.

Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, Lang JM, Gastaut JA, Touraine JL.

AIDS. 2000 Jan 7;14(1):37-49.

PMID:
10714566
7.

Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.

Tavassoli N, Bagheri H, Sommet A, Delpierre C, Marion-Latard F, Massip P, Aquilina C, Bonnet E, Obadia M, Labau E, Montastruc JL, Bernard J.

Pharmacotherapy. 2006 Feb;26(2):154-61.

PMID:
16466321
8.

Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.

Galli M, Ridolfo AL, Adorni F, Cappelletti A, Morelli P, Massetto B, Piazza M, Gianelli E, Vaccarezza M, Gervasoni C, Moroni M.

Antivir Ther. 2003 Aug;8(4):347-54.

PMID:
14518704
9.

Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors.

Melvin AJ, Lennon S, Mohan KM, Purnell JQ.

AIDS Res Hum Retroviruses. 2001 Aug 10;17(12):1117-23.

PMID:
11522181
10.

Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.

Martínez E, Conget I, Lozano L, Casamitjana R, Gatell JM.

AIDS. 1999 May 7;13(7):805-10.

PMID:
10357379
11.

Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors.

Galli M, Ridolfo AL, Adorni F, Gervasoni C, Ravasio L, Corsico L, Gianelli E, Piazza M, Vaccarezza M, d'Arminio Monforte A, Moroni M.

J Acquir Immune Defic Syndr. 2002 Jan 1;29(1):21-31.

PMID:
11782586
12.

Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.

Guaraldi G, Zona S, Orlando G, Carli F, Stentarelli C, Luzi K, Garlassi E, Menozzi M, Bagni P, Adorni F.

Clin Drug Investig. 2011 Nov 1;31(11):759-67. doi: 10.2165/11593920-000000000-00000.

PMID:
21919542
13.

Fat redistribution in indinavir-treated patients with HIV infection: A review of postmarketing cases.

Benson JO, McGhee K, Coplan P, Grunfeld C, Robertson M, Brodovicz KG, Slater E.

J Acquir Immune Defic Syndr. 2000 Oct 1;25(2):130-9. Review.

PMID:
11103043
14.

Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART).

Dong KL, Bausserman LL, Flynn MM, Dickinson BP, Flanigan TP, Mileno MD, Tashima KT, Carpenter CC.

J Acquir Immune Defic Syndr. 1999 Jun 1;21(2):107-13.

PMID:
10360801
15.
16.

[Abnormal body fat distribution and type of antiretroviral therapy as predictors of cardiovascular disease risk in HIV-infected patients].

Ena J, Benito C, Llácer P, Pasquau F, Amador C.

Med Clin (Barc). 2004 May 22;122(19):721-6. Spanish.

PMID:
15171905
17.

Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.

Duvivier C, Ghosn J, Assoumou L, Soulié C, Peytavin G, Calvez V, Génin MA, Molina JM, Bouchaud O, Katlama C, Costagliola D; ANRS 121 study group.

J Antimicrob Chemother. 2008 Oct;62(4):797-808. doi: 10.1093/jac/dkn278. Epub 2008 Jul 18.

18.

Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome.

Kosmiski LA, Kuritzkes DR, Lichtenstein KA, Glueck DH, Gourley PJ, Stamm ER, Scherzinger AL, Eckel RH.

AIDS. 2001 Oct 19;15(15):1993-2000.

PMID:
11600828
19.

HIV lipodystrophy: prevalence, severity and correlates of risk in Australia.

Miller J, Carr A, Emery S, Law M, Mallal S, Baker D, Smith D, Kaldor J, Cooper DA.

HIV Med. 2003 Jul;4(3):293-301.

20.

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.

Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA.

AIDS. 1998 May 7;12(7):F51-8.

PMID:
9619798
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk